Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Change in Interest Receivables (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed Change in Interest Receivables for 4 consecutive years, with $485.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Interest Receivables fell 88.65% to $485.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$594.0, a 107.25% decrease, with the full-year FY2024 number at $23604.0, up 101.87% from a year prior.
  • Change in Interest Receivables was $485.0 for Q3 2025 at 60 Degrees Pharmaceuticals, down from $1025.0 in the prior quarter.
  • In the past five years, Change in Interest Receivables ranged from a high of $158346.0 in Q3 2023 to a low of -$856914.0 in Q3 2022.
  • A 4-year average of -$211298.8 and a median of $790.0 in 2024 define the central range for Change in Interest Receivables.
  • Peak YoY movement for Change in Interest Receivables: soared 657.94% in 2024, then tumbled 2610.11% in 2025.
  • 60 Degrees Pharmaceuticals' Change in Interest Receivables stood at -$629868.0 in 2022, then soared by 100.37% to $2342.0 in 2023, then skyrocketed by 657.94% to $17751.0 in 2024, then tumbled by 97.27% to $485.0 in 2025.
  • Per Business Quant, the three most recent readings for SXTP's Change in Interest Receivables are $485.0 (Q3 2025), $1025.0 (Q2 2025), and -$19855.0 (Q1 2025).